Positron Corporation Announces Sale of Attrius PET and NeuSight PET-CT Scanners
Positron (OTC: POSC) has announced the sale of its Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist. The Attrius, a 2D quantitative dedicated PET scanner, provides high-resolution images and blood flow data for coronary flow reserve analysis. The NeuSight PET-CT features a spacious 72 cm gantry and high-sensitivity acquisition technology, reducing radiation exposure while maintaining superior imaging capabilities.
The NeuSight PET-CT system, notable for its smallest footprint and lightest weight in its class, supports both cardiology and oncology applications. It enables faster, more precise scans for heart, tumor, and brain studies. The company's president, Adel Abdullah, highlighted these sales as indicators of growing market momentum and emphasized their technology's role in advancing PET imaging and cardiovascular care.
Positron (OTC: POSC) ha annunciato la vendita dei suoi sistemi di imaging nucleare Attrius PET e NeuSight PET-CT 64 a un importante specialista in cardiologia. L'Attrius, uno scanner PET dedicato quantitativo 2D, fornisce immagini ad alta risoluzione e dati sul flusso sanguigno per l'analisi della riserva di flusso coronarico. Il NeuSight PET-CT presenta un gantry spazioso da 72 cm e tecnologia di acquisizione ad alta sensibilità, riducendo l'esposizione alle radiazioni pur mantenendo capacità di imaging superiori.
Il sistema NeuSight PET-CT, noto per la sua minore impronta e il suo peso più leggero nella sua categoria, supporta sia le applicazioni cardiologiche che quelle oncologiche. Consente scansioni più veloci e precise per studi sul cuore, tumori e cervello. Il presidente dell'azienda, Adel Abdullah, ha sottolineato queste vendite come indicatori di una crescente momentum di mercato e ha enfatizzato il ruolo della loro tecnologia nel migliorare l'imaging PET e la cura cardiovascolare.
Positron (OTC: POSC) ha anunciado la venta de sus sistemas de imagen nuclear Attrius PET y NeuSight PET-CT 64 a un destacado especialista en cardiología. El Attrius, un escáner PET cuantitativo 2D, proporciona imágenes de alta resolución y datos de flujo sanguíneo para el análisis de la reserva de flujo coronario. El NeuSight PET-CT cuenta con un gantry espacioso de 72 cm y tecnología de adquisición de alta sensibilidad, reduciendo la exposición a la radiación mientras mantiene capacidades de imagen superiores.
El sistema NeuSight PET-CT, notable por su menor tamaño y peso más ligero en su clase, apoya aplicaciones tanto en cardiología como en oncología. Permite escaneos más rápidos y precisos para estudios del corazón, tumores y cerebro. El presidente de la compañía, Adel Abdullah, destacó estas ventas como indicadores de un creciente impulso en el mercado y enfatizó el papel de su tecnología en el avance de la imagen PET y el cuidado cardiovascular.
포지트론 (OTC: POSC)은 저명한 심장 전문의에게 Attrius PET 및 NeuSight PET-CT 64 슬라이스 핵 이미징 시스템의 판매를 발표했습니다. Attrius는 2D 정량적 전용 PET 스캐너로, 관상동맥 유속 분석을 위한 고해상도 이미지와 혈류 데이터를 제공합니다. NeuSight PET-CT는 72cm의 넓은 간트리와 고감도 획득 기술을 특징으로 하며, 방사선 노출을 줄이면서 우수한 이미징 기능을 유지합니다.
NeuSight PET-CT 시스템은 클래스에서 가장 작은 공간을 차지하고 가장 가벼운 무게로, 심장병과 종양학 응용 프로그램을 모두 지원합니다. 심장, 종양 및 뇌 연구를 위한 더 빠르고 정확한 스캔을 가능하게 합니다. 회사의 사장인 아델 압둘라(Adel Abdullah)는 이러한 판매를 시장의 증가하는 모멘텀의 지표로 강조하며, PET 이미징 및 심혈관 치료를 발전시키는 데 있어 그들의 기술의 역할을 강조했습니다.
Positron (OTC: POSC) a annoncé la vente de ses systèmes d'imagerie nucléaire Attrius PET et NeuSight PET-CT 64 à un spécialiste en cardiologie de renom. L'Attrius, un scanner PET quantitatif 2D dédié, fournit des images haute résolution et des données de flux sanguin pour l'analyse de la réserve de flux coronaire. Le NeuSight PET-CT est doté d'un grand gantry de 72 cm et d'une technologie d'acquisition haute sensibilité, réduisant l'exposition aux radiations tout en maintenant des capacités d'imagerie supérieures.
Le système NeuSight PET-CT, remarquable pour sa plus petite empreinte et son poids le plus léger de sa catégorie, prend en charge les applications en cardiologie et en oncologie. Il permet des scans plus rapides et plus précis pour les études sur le cœur, les tumeurs et le cerveau. Le président de l'entreprise, Adel Abdullah, a souligné ces ventes comme des indicateurs d'un dynamisme croissant sur le marché et a souligné le rôle de sa technologie dans l'avancement de l'imagerie PET et des soins cardiovasculaires.
Positron (OTC: POSC) hat den Verkauf seiner Attrius PET und NeuSight PET-CT 64 Schnitt-Nuklearmedizin-Bildsysteme an einen renommierten Kardiologen bekannt gegeben. Der Attrius, ein 2D-quantitatives, spezialisiertes PET-Scanner, liefert hochauflösende Bilder und Blutflussdaten zur Analyse der koronaren Flussreserve. Das NeuSight PET-CT verfügt über einen geräumigen 72 cm großen Gantry und eine hochsensible Erfassungstechnologie, die die Strahlenbelastung reduziert und gleichzeitig überlegene Bildgebungsfähigkeiten bietet.
Das NeuSight PET-CT-System, das sich durch seine kleinste Stellfläche und das leichteste Gewicht in seiner Klasse auszeichnet, unterstützt sowohl kardiologische als auch onkologische Anwendungen. Es ermöglicht schnellere, präzisere Scans für Studien zu Herz, Tumoren und Gehirn. Der Präsident des Unternehmens, Adel Abdullah, hob diese Verkäufe als Indikatoren für das wachsende Marktengagement hervor und betonte die Rolle ihrer Technologie bei der Verbesserung der PET-Bildgebung und der kardiovaskulären Versorgung.
- Secured new sales of two major imaging systems (Attrius PET and NeuSight PET-CT)
- Growing market momentum indicated by sales to prominent specialist
- Competitive advantage with smallest footprint and lightest weight PET-CT system in market
- None.
Niagara Falls, NY, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices.
The Attrius is a 2D quantitative dedicated PET scanner optimized for nuclear cardiology. The Attrius provides high-resolution images in tandem with robust blood flow data for analysis optimal for the latest in coronary flow reserve software, assisting the generation of accurate measurements of absolute blood flow and coronary flow reserve.
The NeuSight PET-CT is designed to transform cardiac PET imaging by combining exceptional performance, advanced technology, and unmatched value. Renowned for its top-tier performance and international success, the NeuSight PET-CT stands out with its patient-centered design, featuring a spacious 72 cm gantry for enhanced comfort and high-sensitivity acquisition technology that minimizes radiation exposure for both patients and technicians. With the smallest footprint and lightest weight among PET-CT systems, it offers superior imaging capabilities while optimizing space utilization, making it an ideal solution for modern healthcare facilities.
As a cost-effective and innovative system, the NeuSight PET-CT excels in both cardiology and oncology clinical studies. Its advanced data acquisition and identification technology enable faster and more precise scans, improving diagnostic accuracy. Offering both anatomic and functional imaging, the NeuSight PET-CT supports a wide range of molecular imaging applications, including heart, tumor, and brain studies, showcasing its versatility and commitment to advancing medical diagnostics.
Adel Abdullah, President of Positron stated, “We are pleased that esteemed physicians in the nuclear cardiovascular field recognize the advantages of our systems and services. These recent sales are very positive indicators of our growing momentum in the marketplace. We believe our technology, comprehensive support and unmatched value uniquely position us to advance the adoption of PET imaging and cardiovascular care." Mr. Abdullah added, "We are thrilled to work with such a distinguished physician dedicated to providing expert care. We look forward to supporting their growth and ensuring they fully utilize the capabilities of our Attrius PET and NeuSight PET-CT systems in delivering outstanding outcomes for their patients.”
About Positron Corporation
Positron Corporation is a medical technology company that co-develops, manufactures, and sells state-of-the-art PET and PET-CT imaging systems and clinical services to nuclear medicine healthcare providers throughout North America.
Positron specializes in the field of cardiac Positron Emission Tomography (PET) imaging, the gold standard in cardiac diagnostics. Positron’s innovative PET/PET-CT technologies, clinical services and practice solutions enables healthcare providers to accurately diagnose coronary artery disease and improve patient outcomes while practicing cost effective medicine.
Positron's Attrius® PET and NeuSight PET-CT imaging systems and distinct market position are substantial advantages unique to Positron that will facilitate the adoption of cardiac PET and the growth of the nuclear imaging market. Positron will soon offer a state-of-the-art PET-CT 4D molecular imaging device in the Affinity PET-CT 4D 64-Slice. Positron’s PET-CT(s) will enable nuclear cardiologists to utilize the full capabilities of molecular imaging and nuclear medicine. Positron’s PET-CT systems will also enable the Company to fully service and meet the demands of the vast oncology imaging segment of nuclear medicine.
Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to imaging specialists and will continue to advance its technology through its co-developer, supplier, and R&D venture with Shenyang Intelligent Neuclear Technology Co. a subsidiary of Neusoft Medical Systems.
Please visit the Company’s website at: www.positron.com
Forward-Looking Statements
This press release contains statements which may constitute "forward-looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of Positron Corporation, and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results even if new information becomes available in the future.
FOR FURTHER INFORMATION, please visit the company’s website at www.positron.com, or contact: investor@positron.com
FAQ
What imaging systems did Positron (POSC) sell in January 2025?
What are the key features of POSC's NeuSight PET-CT system?
What capabilities does POSC's Attrius PET scanner offer?
How does POSC's NeuSight PET-CT system benefit medical facilities?
